Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUC-MSCs for Severe Viral Pneumonia
NCT04282928Phase 1Unknown
- Sponsor
- Shanghai East Hospital
- Start
- Feb 2020
- Primary completion
- Jan 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human umbilical cord mesenchymal stem cells in viral pneumonia (2 arms), sponsored by Shanghai East Hospital. Primary endpoints: Mortality at 90 days and Average Length of Stay at 90 days. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
viral pneumonia
Beyond the preview
Go deeper on NCT04282928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282928.